News and Announcements
ChimpChange Raises $10m
- Published May 19, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ChimpChange Limited (ASX: CCA), Australia’s only listed digital banking platform, is pleased to announce the successful completion of a placement to institutional and sophisticated investors.
The Placement will raise approximately $10 million, through the issue of 13,888,889 new ordinary shares at an issue price of $0.72 per share. The Placement was managed by CCZ Corporate Finance Limited and Morgans Corporate Limited.
KEY TAKEAWAYS:
- Successfully completes oversubscribed placement raising $10 million
- Placement supported by a number of well respected Australian institutional fund managers including a cornerstone investment by Acorn Capital Limited
- ChimpChange now well-funded to accelerate customer acquisition, product development and finalise build-out of internal enterprise software development capabilities
ChimpChange’s Managing Director, Ashley Shilkin commented – “We are thrilled to have the support of a number of well respected Australian institutional fund managers as well as professional investors and welcome Acorn Capital as a substantial shareholder to the register.
Together with current funds and the Placement proceeds, the Company is now in a strong financial position to continue to execute on our stated objectives and continue the incredible growth we have been demonstrating since our listing ten months ago.”
ChimpChange shares are expected to resume trading today, Friday 19 May 2017. The Placement is expected to settle on 24 May 2017, with allotment the following business day.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
